Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MYOMO, INC.

(MYO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Myomo, Inc. : Announces Participation in A.G.P.'s Virtual MedTech Summer Conference on July 29, 2021

07/23/2021 | 04:06pm EDT

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will participate in A.G.P.’s Virtual MedTech Summer Conference on Thursday, July 29, 2021.

The event will consist of one-on-one virtual investor meetings. Investors participating in the virtual conference who are interested in meeting with members of Myomo’s management team should contact their A.G.P. representative.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally. For more information, please visit www.myomo.com.


ę Business Wire 2021
All news about MYOMO, INC.
09/08MYOMO : Investor Presentation September 2021
PU
09/07MYOMO, INC. : Announces Granting of Patents in China and Hong Kong
BU
09/02MYOMO, INC. : Announces Participation in Three September Investment Conferences
BU
08/10MYOMO : Investor Presentation August 2021
PU
08/09MYOMO : Earnings Flash (MYO) MYOMO Posts Q2 Revenue $3.1M
MT
08/09MYOMO : Management's Discussion and Analysis of Financial Condition and Results of Operati..
AQ
08/09MYOMO, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
08/09Myomo, Inc. Provides Revenue Guidance for the Third Quarter of 2021
CI
08/09MYOMO : Second Quarter 2021 Financial Results Feature Significant Increases in Revenue and..
BU
08/09Myomo, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
More news
Analyst Recommendations on MYOMO, INC.
More recommendations
Financials (USD)
Sales 2021 12,6 M - -
Net income 2021 -10,1 M - -
Net cash 2021 9,14 M - -
P/E ratio 2021 -6,58x
Yield 2021 -
Capitalization 67,9 M 67,9 M -
EV / Sales 2021 4,66x
EV / Sales 2022 3,73x
Nbr of Employees 63
Free-Float 95,6%
Chart MYOMO, INC.
Duration : Period :
Myomo, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYOMO, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 11,85 $
Average target price 22,20 $
Spread / Average Target 87,3%
EPS Revisions
Managers and Directors
Paul R. Gudonis Chairman, President & Chief Executive Officer
David A. Henry Chief Financial & Accounting Officer
Harry Kovelman Chief Medical Officer
Stefanie Dunaway Manager-Clinical Services
Thomas A. Crowley Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MYOMO, INC.76.08%68
ABBOTT LABORATORIES14.05%221 372
MEDTRONIC PLC9.89%173 246
BECTON, DICKINSON AND COMPANY3.62%74 460
HOYA CORPORATION29.05%62 558
SARTORIUS STEDIM BIOTECH78.64%56 275